Source comparison
GHRP-2 vs Ipamorelin: The Biased Agonism Explanation
The selectivity difference in the GHRP-2 vs Ipamorelin comparison likely reflects biased agonism at the GHS-R1a receptor. Both peptides bind the same receptor, but Ipamorelin’s specific molecular configuration (Aib-His-D-2Nal-D-Phe-Lys-NH₂) appears to stabiliz
This comparison does not assign a generated winner or score.
- The selectivity difference in the GHRP-2 vs Ipamorelin comparison likely reflects biased agonism at the GHS-R1a receptor. Both peptides bind the same receptor, but Ipamorelin’s specific molecular configuration (Aib-His-D-2Nal-D-Phe-Lys-NH₂) appears to stabilize the receptor in a conformation that preferentially activates the somatotroph GH-release pathway while minimizing activation of corticotroph and lactotroph signaling. GHRP-2’s broader structure (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH₂) activates the receptor more broadly, engaging multiple downstream pathways simultaneously.
- This biased agonism explanation for the GHRP-2 vs Ipamorelin selectivity difference remains an active area of pharmacological research — the precise structural determinants of pathway selectivity at GHS-R1a are not yet fully characterized. For practical research purposes, the GHRP-2 vs Ipamorelin difference is well-established empirically: GHRP-2 produces more GH with more side effects; Ipamorelin produces less GH with fewer side effects.